Targeting adenosine A2A receptor antagonism for treatment of cancer
暂无分享,去创建一个
Michelle L. Lamb | Miles Congreve | M. Congreve | M. Lamb | A. Borodovsky | Giles A. Brown | Alexandra Borodovsky
[1] Francesca Deflorian,et al. High end GPCR design: crafted ligand design and druggability analysis using protein structure, lipophilic hotspots and explicit water networks , 2013, In Silico Pharmacology.
[2] S. Loi,et al. Abstract CT119: CPI-444, an oral adenosine A2a receptor (A2aR) antagonist, demonstrates clinical activity in patients with advanced solid tumors , 2017 .
[3] S. Antonia,et al. A Novel Antagonist of the Immune Checkpoint Protein Adenosine A2a Receptor Restores Tumor-Infiltrating Lymphocyte Activity in the Context of the Tumor Microenvironment , 2017, Neoplasia.
[4] Brian K. Shoichet,et al. Structure-Based Discovery of A2A Adenosine Receptor Ligands , 2010, Journal of medicinal chemistry.
[5] Nathan Robertson,et al. Article pubs.acs.org/jmc Identification of Novel Adenosine A 2A Receptor Antagonists by Virtual Screening , 2022 .
[6] M. Congreve,et al. Structure of the adenosine A(2A) receptor in complex with ZM241385 and the xanthines XAC and caffeine. , 2011, Structure.
[7] Ruben Abagyan,et al. Optimization of adenosine 5'-carboxamide derivatives as adenosine receptor agonists using structure-based ligand design and fragment screening. , 2012, Journal of medicinal chemistry.
[8] Dov Barak,et al. Evaluation of homology modeling of G-protein-coupled receptors in light of the A(2A) adenosine receptor crystallographic structure. , 2009, Journal of medicinal chemistry.
[9] David M. Conrad,et al. Inhibition of T cell and natural killer cell function by adenosine and its contribution to immune evasion by tumor cells (Review). , 2008, International journal of oncology.
[10] M. Smyth,et al. Targeting CD73 Enhances the Antitumor Activity of Anti-PD-1 and Anti-CTLA-4 mAbs , 2013, Clinical Cancer Research.
[11] J. Linden,et al. Adenosine A2A receptors intrinsically regulate CD8+ T cells in the tumor microenvironment. , 2014, Cancer research.
[12] Stefano Moro,et al. Bridging Molecular Docking to Membrane Molecular Dynamics To Investigate GPCR-Ligand Recognition: The Human A2A Adenosine Receptor as a Key Study , 2014, J. Chem. Inf. Model..
[13] B. Shook,et al. Adenosine A(2A) Receptor Antagonists and Parkinson's Disease. , 2011, ACS chemical neuroscience.
[14] E. Morris,et al. Phase I/II study of the A2AR antagonist NIR178 (PBF-509), an oral immunotherapy, in patients (pts) with advanced NSCLC. , 2018 .
[15] Stephen P. H. Alexander,et al. [3H]ZM241385—an antagonist radioligand for adenosine A2A receptors in rat brain , 2001 .
[16] B. Neustadt,et al. Characterization of the Potent and Highly Selective A2A Receptor Antagonists Preladenant and SCH 412348 [7-[2-[4-2,4-Difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] in Rodent Models of Movement Disorders and Depression , 2009, Journal of Pharmacology and Experimental Therapeutics.
[17] N. Wald,et al. Abstract LB-291: EOS100850, an insurmountable and non-brain penetrant A2A receptor antagonist, inhibits adenosine-mediated T cell suppression, demonstrates anti-tumor activity and exhibits best-in class characteristics , 2018 .
[18] R. Hodgson,et al. Recent progress in the discovery of adenosine A(2A) receptor antagonists for the treatment of Parkinson's disease. , 2010, Current opinion in drug discovery & development.
[19] S. Loi,et al. CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer , 2013, Proceedings of the National Academy of Sciences.
[20] Andrzej J. Bojarski,et al. Impact of Template Choice on Homology Model Efficiency in Virtual Screening , 2014, J. Chem. Inf. Model..
[21] Neha Singh,et al. Advances in the treatment of Parkinson's disease , 2007, Progress in Neurobiology.
[22] L. Grégoire,et al. Preladenant, a selective A2A receptor antagonist, is active in primate models of movement disorders , 2010, Experimental Neurology.
[23] Andrew S Doré,et al. Towards high throughput GPCR crystallography: In Meso soaking of Adenosine A2A Receptor crystals , 2018, Scientific Reports.
[24] M. Idzko,et al. Adenosine affects expression of membrane molecules, cytokine and chemokine release, and the T-cell stimulatory capacity of human dendritic cells. , 2003, Blood.
[25] D. Carbone,et al. Adenosine receptors in regulation of dendritic cell differentiation and function. , 2008, Blood.
[26] R. Stevens,et al. The 2.6 Angstrom Crystal Structure of a Human A2A Adenosine Receptor Bound to an Antagonist , 2008, Science.
[27] Jiayu Wen,et al. Inhibition of the adenosine A2a receptor modulates expression of T cell coinhibitory receptors and improves effector function for enhanced checkpoint blockade and ACT in murine cancer models , 2018, Cancer Immunology, Immunotherapy.
[28] Stephen P. H. Alexander,et al. [(3)H]ZM241385--an antagonist radioligand for adenosine A(2A) receptors in rat brain. , 2001, European Journal of Pharmacology.
[29] M. Curran,et al. Regadenoson , 2010, American Journal of Cardiovascular Drugs.
[30] M. Smyth,et al. CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis. , 2011, Cancer research.
[31] R. Hollingsworth,et al. Targeting CD73 in the tumor microenvironment with MEDI9447 , 2016, Oncoimmunology.
[32] R. Stevens,et al. Structural Basis for Allosteric Regulation of GPCRs by Sodium Ions , 2012, Science.
[33] T. Ceska,et al. Crystal structure of the adenosine A2A receptor bound to an antagonist reveals a potential allosteric pocket , 2017, Proceedings of the National Academy of Sciences.
[34] Catarina Gomes,et al. Adenosine receptors and brain diseases: neuroprotection and neurodegeneration. , 2011, Biochimica et biophysica acta.
[35] Ali Jazayeri,et al. Structurally Enabled Discovery of Adenosine A2A Receptor Antagonists. , 2017, Chemical reviews.
[36] M. Smyth,et al. CD73: a potent suppressor of antitumor immune responses. , 2012, Trends in immunology.
[37] Manuel de Lera Ruiz,et al. Adenosine A2A receptor as a drug discovery target. , 2014, Journal of medicinal chemistry.
[38] J. Powell,et al. A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy , 2015, Computational and structural biotechnology journal.
[39] S. P. Andrews,et al. Structure-based drug design of chromone antagonists of the adenosine A2A receptor , 2014 .
[40] J. Åqvist,et al. Structure-Based Design of Potent and Selective Ligands at the Four Adenosine Receptors , 2017, Molecules.
[41] G. Marucci,et al. Adenosine receptor modeling: what does the A2A crystal structure tell us? , 2010, Current topics in medicinal chemistry.
[42] J. Powell,et al. Adenosine and anergy , 2007, Autoimmunity.
[43] A. Leslie,et al. Agonist-bound adenosine A2A receptor structures reveal common features of GPCR activation , 2011, Nature.
[44] Fei Xu,et al. Evaluation of molecular modeling of agonist binding in light of the crystallographic structure of an agonist-bound A₂A adenosine receptor. , 2012, Journal of medicinal chemistry.
[45] C. Tate,et al. Expression, Purification and Crystallisation of the Adenosine A2A Receptor Bound to an Engineered Mini G Protein. , 2017, Bio-protocol.
[46] R. Stevens,et al. Structure of an Agonist-Bound Human A2A Adenosine Receptor , 2011, Science.
[47] Deborah S. Barkauskas,et al. Adenosine 2B Receptor Expression on Cancer Cells Promotes Metastasis. , 2016, Cancer research.
[48] Gregg Siegal,et al. Fragment screening of GPCRs using biophysical methods: identification of ligands of the adenosine A(2A) receptor with novel biological activity. , 2012, ACS chemical biology.
[49] Gregg Siegal,et al. Fragment screening of stabilized G-protein-coupled receptors using biophysical methods. , 2011, Methods in enzymology.
[50] K. Fuxe,et al. Kinetic and functional properties of [3H]ZM241385, a high affinity antagonist for adenosine A2A receptors. , 2005, Life sciences.
[51] Ruben Abagyan,et al. Structure-based discovery of novel chemotypes for adenosine A(2A) receptor antagonists. , 2010, Journal of medicinal chemistry.
[52] B. Schraven,et al. Adenosine regulates CD8 T‐cell priming by inhibition of membrane‐proximal T‐cell receptor signalling , 2009, Immunology.
[53] Christopher G Tate,et al. Cryo-EM structure of the adenosine A2A receptor coupled to an engineered heterotrimeric G protein , 2018, bioRxiv.
[54] S. P. Andrews,et al. Stabilised G protein-coupled receptors in structure-based drug design: a case study with adenosine A2A receptor , 2013 .
[55] C. Müller,et al. Nanodiscs for INPHARMA NMR Characterization of GPCRs: Ligand Binding to the Human A2A Adenosine Receptor. , 2017, Angewandte Chemie.
[56] Deborah S. Barkauskas,et al. Co-inhibition of CD73 and A2AR Adenosine Signaling Improves Anti-tumor Immune Responses. , 2016, Cancer cell.
[57] Nathan Robertson,et al. Biophysical Mapping of the Adenosine A2A Receptor , 2011, Journal of medicinal chemistry.
[58] W. Dauer,et al. Parkinson's Disease Mechanisms and Models , 2003, Neuron.
[59] U. Schindler,et al. Abstract 1756: Discovery and characterization of AB680, a potent and selective small-molecule CD73 inhibitor for cancer immunotherapy , 2018, Immunology.
[60] Jonathan W. Essex,et al. Water Network Perturbation in Ligand Binding: Adenosine A2A Antagonists as a Case Study , 2013, J. Chem. Inf. Model..
[61] J. Errey,et al. Biacore analysis with stabilized G-protein-coupled receptors. , 2011, Analytical biochemistry.
[62] E. Deeks,et al. Istradefylline: First Global Approval , 2013, Drugs.
[63] A. Leslie,et al. Molecular Determinants of CGS21680 Binding to the Human Adenosine A2A Receptor , 2015, Molecular Pharmacology.
[64] Ruben Abagyan,et al. Structure based prediction of subtype-selectivity for adenosine receptor antagonists , 2011, Neuropharmacology.
[65] A. Hotson,et al. Abstract 2337: The adenosine A2A receptor antagonist CPI-444 blocks adenosine-mediated T-cell suppression and exhibits antitumor activity alone and in combination with anti-PD-1 and anti-PD-L1 , 2016 .
[66] E. Dmitrovsky,et al. CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade. , 2018, Cancer discovery.
[67] James D. Clarke,et al. Abstract 5580: Preclinical pharmacodynamics and antitumor activity of AZD4635, a novel adenosine 2A receptor inhibitor that reverses adenosine mediated T cell suppression , 2017 .
[68] Hugo Gutiérrez-de-Terán,et al. Ligand-, structure- and pharmacophore-based molecular fingerprints: a case study on adenosine A1, A2A, A2B, and A3 receptor antagonists , 2012, Journal of Computer-Aided Molecular Design.
[69] Yitian Chen,et al. Expression and clinical significance of CD73 and hypoxia-inducible factor-1α in gastric carcinoma. , 2013, World journal of gastroenterology.
[70] Enabling STD-NMR fragment screening using stabilized native GPCR: A case study of adenosine receptor , 2018, Scientific Reports.
[71] A. Leslie,et al. Structure of the adenosine A2A receptor bound to an engineered G protein , 2016, Nature.
[72] K. Varani,et al. History and Perspectives of A2A Adenosine Receptor Antagonists as Potential Therapeutic Agents , 2015, Medicinal research reviews.
[73] S. Iwata,et al. G protein-coupled receptor inactivation by an allosteric inverse-agonist antibody , 2011, Nature.
[74] C. Higgs,et al. Hydration Site Thermodynamics Explain SARs for Triazolylpurines Analogues Binding to the A2A Receptor. , 2010, ACS medicinal chemistry letters.
[75] A. Ohta,et al. The development and immunosuppressive functions of CD4+ CD25+ FoxP3+ regulatory T cells are under influence of the adenosine-A2A adenosine receptor pathway , 2012, Front. Immun..
[76] Andrea Bortolato,et al. New insights from structural biology into the druggability of G protein-coupled receptors. , 2012, Trends in pharmacological sciences.
[77] R. Franco,et al. Adenosine A2A Receptor Antagonists in Neurodegenerative Diseases: Huge Potential and Huge Challenges , 2018, Front. Psychiatry.
[78] Jonathan S. Mason,et al. Structures of G protein-coupled receptors reveal new opportunities for drug discovery. , 2015, Drug discovery today.
[79] J. Schrader,et al. Turnover of adenosine in plasma of human and dog blood. , 1989, The American journal of physiology.
[80] A. Ohta,et al. A2A adenosine receptor protects tumors from antitumor T cells , 2006, Proceedings of the National Academy of Sciences.
[81] Jonathan S. Mason,et al. Discovery of 1,2,4-Triazine Derivatives as Adenosine A2A Antagonists using Structure Based Drug Design , 2012, Journal of medicinal chemistry.
[82] Deborah S. Barkauskas,et al. A2AR Adenosine Signaling Suppresses Natural Killer Cell Maturation in the Tumor Microenvironment. , 2018, Cancer research.
[83] Deborah S. Barkauskas,et al. Selective activation of anti-CD73 mechanisms in control of primary tumors and metastases , 2017, Oncoimmunology.
[84] J. Blay,et al. The extracellular fluid of solid carcinomas contains immunosuppressive concentrations of adenosine. , 1997, Cancer research.
[85] Xiaojian Wu,et al. High expression of CD73 as a poor prognostic biomarker in human colorectal cancer , 2012, Journal of surgical oncology.